rs147150415

Variant summary

Our verdict is Benign. The variant received -9 ACMG points: 0P and 9B. BP4_StrongBS1_SupportingBS2

The NM_001290043.2(TAP2):​c.1776G>A​(p.Met592Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00103 in 1,613,098 control chromosomes in the GnomAD database, including 4 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).

Frequency

Genomes: 𝑓 0.00073 ( 0 hom., cov: 33)
Exomes 𝑓: 0.0011 ( 4 hom. )

Consequence

TAP2
NM_001290043.2 missense

Scores

1
9
8

Clinical Significance

Uncertain significance criteria provided, multiple submitters, no conflicts U:4

Conservation

PhyloP100: 0.171

Publications

6 publications found
Variant links:
Genes affected
TAP2 (HGNC:44): (transporter 2, ATP binding cassette subfamily B member) The membrane-associated protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the MDR/TAP subfamily. Members of the MDR/TAP subfamily are involved in multidrug resistance. This gene is located 7 kb telomeric to gene family member ABCB2. The protein encoded by this gene is involved in antigen presentation. This protein forms a heterodimer with ABCB2 in order to transport peptides from the cytoplasm to the endoplasmic reticulum. Mutations in this gene may be associated with ankylosing spondylitis, insulin-dependent diabetes mellitus, and celiac disease. Alternative splicing of this gene produces products which differ in peptide selectivity and level of restoration of surface expression of MHC class I molecules. [provided by RefSeq, Feb 2014]
TAP2 Gene-Disease associations (from GenCC):
  • MHC class I deficiency
    Inheritance: AR Classification: STRONG, MODERATE, SUPPORTIVE Submitted by: Orphanet, Ambry Genetics, Labcorp Genetics (formerly Invitae), ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -9 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.034795314).
BS1
Variant frequency is greater than expected in population amr. GnomAd4 allele frequency = 0.000729 (111/152310) while in subpopulation AMR AF = 0.00118 (18/15308). AF 95% confidence interval is 0.00076. There are 0 homozygotes in GnomAd4. There are 55 alleles in the male GnomAd4 subpopulation. Median coverage is 33. This position passed quality control check. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
BS2
High Homozygotes in GnomAdExome4 at 4 AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
TAP2NM_001290043.2 linkc.1776G>A p.Met592Ile missense_variant Exon 10 of 12 ENST00000374897.4 NP_001276972.1
TAP2NM_018833.3 linkc.1776G>A p.Met592Ile missense_variant Exon 10 of 12 NP_061313.2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
TAP2ENST00000374897.4 linkc.1776G>A p.Met592Ile missense_variant Exon 10 of 12 1 NM_001290043.2 ENSP00000364032.3
ENSG00000250264ENST00000452392.2 linkc.1776G>A p.Met592Ile missense_variant Exon 10 of 15 2 ENSP00000391806.2

Frequencies

GnomAD3 genomes
AF:
0.000729
AC:
111
AN:
152192
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.000772
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00118
Gnomad ASJ
AF:
0.00202
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.0000942
Gnomad MID
AF:
0.00316
Gnomad NFE
AF:
0.000720
Gnomad OTH
AF:
0.00143
GnomAD2 exomes
AF:
0.000624
AC:
154
AN:
246656
AF XY:
0.000617
show subpopulations
Gnomad AFR exome
AF:
0.00119
Gnomad AMR exome
AF:
0.000290
Gnomad ASJ exome
AF:
0.00100
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.000185
Gnomad NFE exome
AF:
0.000975
Gnomad OTH exome
AF:
0.000658
GnomAD4 exome
AF:
0.00106
AC:
1543
AN:
1460788
Hom.:
4
Cov.:
67
AF XY:
0.00103
AC XY:
748
AN XY:
726708
show subpopulations
African (AFR)
AF:
0.000806
AC:
27
AN:
33480
American (AMR)
AF:
0.000268
AC:
12
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.000995
AC:
26
AN:
26136
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39700
South Asian (SAS)
AF:
0.00
AC:
0
AN:
86258
European-Finnish (FIN)
AF:
0.000325
AC:
17
AN:
52332
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5768
European-Non Finnish (NFE)
AF:
0.00126
AC:
1398
AN:
1112004
Other (OTH)
AF:
0.00104
AC:
63
AN:
60386
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.458
Heterozygous variant carriers
0
86
171
257
342
428
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
60
120
180
240
300
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000729
AC:
111
AN:
152310
Hom.:
0
Cov.:
33
AF XY:
0.000739
AC XY:
55
AN XY:
74472
show subpopulations
African (AFR)
AF:
0.000770
AC:
32
AN:
41548
American (AMR)
AF:
0.00118
AC:
18
AN:
15308
Ashkenazi Jewish (ASJ)
AF:
0.00202
AC:
7
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5194
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4832
European-Finnish (FIN)
AF:
0.0000942
AC:
1
AN:
10618
Middle Eastern (MID)
AF:
0.00340
AC:
1
AN:
294
European-Non Finnish (NFE)
AF:
0.000720
AC:
49
AN:
68018
Other (OTH)
AF:
0.00142
AC:
3
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
6
12
18
24
30
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000808
Hom.:
1
Bravo
AF:
0.000971
TwinsUK
AF:
0.00108
AC:
4
ALSPAC
AF:
0.000259
AC:
1
ESP6500AA
AF:
0.00132
AC:
4
ESP6500EA
AF:
0.00148
AC:
8
ExAC
AF:
0.000667
AC:
79
EpiCase
AF:
0.000818
EpiControl
AF:
0.000948

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

MHC class I deficiency Uncertain:3
Oct 14, 2021
Fulgent Genetics, Fulgent Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Oct 16, 2022
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces methionine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 592 of the TAP2 protein (p.Met592Ile). This variant is present in population databases (rs147150415, gnomAD 0.1%), and has an allele count higher than expected for a pathogenic variant. This variant has not been reported in the literature in individuals affected with TAP2-related conditions. ClinVar contains an entry for this variant (Variation ID: 534713). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Not Available"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

Mar 22, 2021
New York Genome Center
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Inborn genetic diseases Uncertain:1
Dec 27, 2023
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.1776G>A (p.M592I) alteration is located in exon 10 (coding exon 9) of the TAP2 gene. This alteration results from a G to A substitution at nucleotide position 1776, causing the methionine (M) at amino acid position 592 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.58
BayesDel_addAF
Benign
-0.20
T
BayesDel_noAF
Benign
-0.11
CADD
Benign
23
DANN
Uncertain
1.0
DEOGEN2
Benign
0.38
.;.;.;T
Eigen
Benign
0.0044
Eigen_PC
Benign
0.0049
FATHMM_MKL
Uncertain
0.92
D
LIST_S2
Uncertain
0.91
D;.;.;.
M_CAP
Uncertain
0.23
D
MetaRNN
Benign
0.035
T;T;T;T
MetaSVM
Uncertain
-0.067
T
MutationAssessor
Benign
1.2
.;L;.;L
PhyloP100
0.17
PrimateAI
Uncertain
0.50
T
PROVEAN
Benign
-1.3
N;N;.;N
REVEL
Uncertain
0.38
Sift
Uncertain
0.0070
D;D;.;D
Sift4G
Uncertain
0.019
.;D;D;D
Polyphen
0.57
.;.;.;P
Vest4
0.35, 0.36, 0.36
MutPred
0.51
Gain of catalytic residue at M592 (P = 0.0668);Gain of catalytic residue at M592 (P = 0.0668);Gain of catalytic residue at M592 (P = 0.0668);Gain of catalytic residue at M592 (P = 0.0668);
MVP
0.59
MPC
0.83
ClinPred
0.060
T
GERP RS
5.3
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Varity_R
0.43
gMVP
0.53
Mutation Taster
=78/22
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.020
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs147150415; hg19: chr6-32797726; API